About Vera Therapeutics, Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://veratx.com/
Frequently Asked Questions
What is the 52-week range for VERA?
The 52-week high is $56.05 and the 52-week low is $23.05.
What is the P/E ratio for VERA?
The P/E ratio data is currently unavailable.
What is the dividend yield for VERA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -84.13%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 5.87.
Analyst Recommendation Trends
Wall Street analyst consensus for VERA over the last few months:
Latest VERA News
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 29, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 16,700 shares of Class A common stock and restricted stock units (RSUs) underlying 8,350 shares of Class A common stock to five (5) new employees under the Inducement Plan. The Compensa
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, from October 22 to 25. The final efficacy analysis of the ORIGIN 3 trial of TRUTAKNA in IgA nephropathy (IgAN) will be a featured late-breaking oral presentation during the opening plenary session and also a late-breaking rese
Vera Therapeutics To Present Multiple Presentations At American Society Of Nephrology Kidney Week 2026 For Its Final Efficacy Analysis Of ORIGIN 3 Study Of TRUTAKNA In IgA Nephropathy
Vera Therapeutics, Inc. (NASDAQ:VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver,
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
VRTX is expanding beyond its CF stronghold with a promising kidney disease pipeline led by povetacicept and inaxaplin.
2 ‘Strong Buy’ Stocks Where a Short Squeeze Could Be Brewing
Should you short stocks right now? That’s a good question, and it’s one with no clear answer. There’s still a bullish feeling in the air, but volatility is rising, and there’s no guarantee the bulls will keep running. In a market like this, it can be tempting to bet against stocks. Shorting a stock can be a fast track to profits, but it’s also a fast track to risk. A short seller borrows shares and sells them, hoping to buy them back later at a lower price. If the stock rises instead, the short
Vicor, Arm Holdings, Micron Technology And Other Big Stocks Moving Higher On Thursday
U.S. stocks rose; Vicor jumped 13.5% on a new license, while Generac surged 19.6% on an Amazon deal. Securitize and biotech shares rallied.
Vera Therapeutics (VERA) Says TRUTAKNA Met All Phase III Endpoints
Vera Therapeutics (NasdaqGM: VERA) reported that TRUTAKNA met all prespecified endpoints in the final Phase III ORIGIN 3 trial for IgA nephropathy. The company said the study showed prevention of disease progression and stabilization of kidney function alongside a favorable safety profile. Management plans to seek full FDA approval for TRUTAKNA later in 2026 through a supplemental biologics license application. The confirmation of TRUTAKNA's Phase III success sits against a wider backdrop of...
Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next
Large-cap healthcare outperformed this week: XLV gained 1.4% through Tuesday, while XBI fell 1.4% and IBB declined 0.5%.
Vera Reverses Its Major Chart Upset As Vertex Rivalry Deepens — What Happened?
Vera stock reversed course Tuesday despite positive results for its kidney disease treatment, a rival to drugs from Otsuka and Vertex.
Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Vera Therapeutics, Inc. (VERA) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 5:35 PM EDTCompany ParticipantsMarshall Fordyce -...
Vera set up for full approval for Trutakna in IgAN with Phase III win
Vera’s Trutakna was granted FDA accelerated approval in IgAN based on 36-week data.
Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results
Vera Therapeutics takes a step toward securing full Food and Drug Administration approval for its injectable kidney drug, Trutakna.
Top Midday Stories: Waystar Reportedly Mulling Potential Sale; Intel-Backed Altera Says Parent Company Files Confidentially for IPO
All three major US stock indexes were down in late-morning trading Tuesday, as Treasury yields conti
Vera Therapeutics: Why I'm Sticking With 'Hold' Despite Today's Positive Trutakna Data
Vera Therapeutics, Inc. gets FDA accelerated approval for Trutakna in IgA nephropathy, but competition and pricing risk remain. Click for this VERA update.
Vera Therapeutics Shares Rise 13% After TRUTAKNA Meets ORIGIN 3 Trial Endpoints
Vera Therapeutics (NASDAQ:VERA) shares rose 13% on Tuesday after the company reported that TRUTAKNA (atacicept-vymj) met all prespecified endpoints in the final efficacy analysis of its ORIGIN 3 trial in adults with primary IgA nephropathy. The company said the results showed that TRUTAKNA stabilised estimated glomerular filtration rate, or eGFR, and reduced kidney disease progression through two years in patients considered at risk of disease progression.
Vera Makes A Bullish Move — Times Three. Will It Hold Up To Competition?
Vera stock jumped Tuesday on positive test results for its kidney disease treatment, a rival to drugs from Otsuka and Vertex Pharmaceuticals.
Sector Update: Healthcare Stocks Fall Pre-Bell Tuesday
Healthcare stocks were falling pre-bell Tuesday, with the State Street Health Care Select Sector SPD
VERA Stock Jumps 16% Premarket – Trutakna Cuts Kidney Disease Progression Risk By 76%, Full FDA Filing Planned In Q4
Vera Therapeutics stated that Trutakna's commercial launch generated more than 350 patient start forms in the first 10 weeks.
What's going on in today's pre-market session
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
What's Going on With Vera Therapeutics Stock on Tuesday?
Vera Therapeutics Phase 3 trial data show that Trutakna significantly reduces kidney disease progression in IgA nephropathy.
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite kidney disease progression benefits.Favorable safety profile, and generally comparable to placebo. Strong commercial launch momentum with over 350 patient start forms generated in the first ten weeks. Plan to submit supplemental BLA to the U.S. Food and Drug Administration (FDA) for full approval in
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 39.3% to $1.56 during Tuesday's pre-market session. The company's market cap stands at $1.1 million. As per the press release, H1 earnings
Vera Therapeutics Announces TRUTAKNA Meets All Prespecified Endpoints Of Final Efficacy Analysis Of ORIGIN 3 Trial In Adults With Primary IgA Nephropathy At Risk For Disease Progression
TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite kidney disease
JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $83
JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and raises the price target from $76 to $83.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-15 | Fordyce Marshall | -18,500 | - | - |
| 2026-09-15 | Fordyce Marshall | -18,500 | $37 | $684,500 |
| 2026-09-15 | Fordyce Marshall | +18,500 | $2.8968 | $53,591 |
| 2026-09-11 | Young Joseph R | -5,000 | - | - |
| 2026-09-11 | Young Joseph R | +5,000 | $3.9396 | $19,698 |
| 2026-09-02 | Fordyce Marshall | -18,500 | - | - |
| 2026-09-02 | Fordyce Marshall | -18,500 | $35.1158 | $649,642 |
| 2026-09-02 | Fordyce Marshall | +18,500 | $2.8968 | $53,591 |
| 2026-08-03 | Boman Nancy Lee | +63,011 | - | - |
| 2026-08-03 | Boman Nancy Lee | +44,987 | - | - |
| 2026-07-07 | Fordyce Marshall | -46,250 | - | - |
| 2026-07-07 | Fordyce Marshall | -2,200 | $43.5947 | $95,908 |
| 2026-07-07 | Fordyce Marshall | -10,500 | $42.8578 | $450,007 |
| 2026-07-07 | Fordyce Marshall | -32,550 | $42.0736 | $1,369,496 |
| 2026-07-07 | Fordyce Marshall | -1,000 | $40.7762 | $40,776 |
| 2026-07-07 | Fordyce Marshall | +46,250 | $2.8968 | $133,977 |
| 2026-07-07 | Fordyce Marshall | -2,200 | $43.5947 | $95,908 |
| 2026-07-07 | Fordyce Marshall | -10,500 | $42.8578 | $450,007 |
| 2026-07-07 | Fordyce Marshall | -32,550 | $42.0736 | $1,369,496 |
| 2026-07-07 | Fordyce Marshall | -1,000 | $40.7762 | $40,776 |
| 2026-06-23 | Fordyce Marshall | -18,500 | - | - |
| 2026-06-23 | Fordyce Marshall | -88 | $38.43 | $3,382 |
| 2026-06-23 | Fordyce Marshall | -18,412 | $37.9311 | $698,387 |
| 2026-06-23 | Fordyce Marshall | +18,500 | $2.8968 | $53,591 |
| 2026-06-23 | Fordyce Marshall | -88 | $38.43 | $3,382 |
| 2026-06-23 | Fordyce Marshall | -18,412 | $37.9311 | $698,387 |
| 2026-05-21 | Hall Kimball | +17,084 | - | - |
| 2026-05-21 | Oliger Christy J. | +17,084 | - | - |
| 2026-05-21 | Cheng Andrew | +17,084 | - | - |
| 2026-05-21 | Morrison Scott W | +17,084 | - | - |
| 2026-05-21 | Meyers James R | +17,084 | - | - |
| 2026-05-21 | ENRIGHT PATRICK G | +17,084 | - | - |
| 2026-05-21 | MORRISSEY MICHAEL | +17,084 | - | - |
| 2026-05-21 | SEIDENBERG BETH C | +17,084 | - | - |
| 2026-05-12 | Fordyce Marshall | -18,500 | - | - |
| 2026-05-12 | Fordyce Marshall | -4,281 | $37.0868 | $158,769 |
| 2026-05-12 | Fordyce Marshall | -14,219 | $36.6396 | $520,978 |
| 2026-05-12 | Fordyce Marshall | +18,500 | $2.8968 | $53,591 |
| 2026-05-12 | Fordyce Marshall | -4,281 | $37.0868 | $158,769 |
| 2026-05-12 | Fordyce Marshall | -14,219 | $36.6396 | $520,978 |
| 2026-04-14 | Fordyce Marshall | -900 | $45.5114 | $40,960 |
| 2026-04-14 | Fordyce Marshall | -7,921 | $44.5784 | $353,106 |
| 2026-04-14 | Fordyce Marshall | -14,130 | $43.6649 | $616,985 |
| 2026-03-23 | Wright-Mitchell Jane | +56,850 | - | - |
| 2026-03-23 | Wright-Mitchell Jane | +42,403 | - | - |
| 2026-03-13 | Young Joseph R | -10,000 | - | - |
| 2026-03-13 | Young Joseph R | +10,000 | $3.9396 | $39,396 |
| 2026-03-05 | Hite Christopher | +24,937 | - | - |
| 2026-02-23 | Skelton Laurence Matthew | -1,582 | $41.9839 | $66,419 |
| 2026-02-23 | Brenner Robert | -2,151 | $41.9839 | $90,307 |
| 2026-02-23 | Grant Sean | -4,949 | $41.9839 | $207,778 |
| 2026-02-23 | Young Joseph R | -3,117 | $41.9839 | $130,864 |
| 2026-02-23 | Fordyce Marshall | -16,925 | $41.9839 | $710,578 |
| 2026-02-23 | Turner William D. | -2,187 | $41.9839 | $91,819 |
| 2026-02-23 | JOHNSON DAVID LEE | -2,579 | $41.9839 | $108,276 |
| 2026-02-04 | Skelton Laurence Matthew | +40,000 | - | - |
| 2026-02-04 | Skelton Laurence Matthew | +20,000 | - | - |
| 2026-02-04 | Brenner Robert | +50,000 | - | - |
| 2026-02-04 | Brenner Robert | +25,000 | - | - |
| 2026-02-04 | Grant Sean | +50,000 | - | - |
| 2026-02-04 | Grant Sean | +25,000 | - | - |
| 2026-02-04 | Young Joseph R | +20,000 | - | - |
| 2026-02-04 | Young Joseph R | +10,000 | - | - |
| 2026-02-04 | Fordyce Marshall | +137,500 | - | - |
| 2026-02-04 | Fordyce Marshall | +68,800 | - | - |
| 2026-02-04 | Turner William D. | +50,000 | - | - |
| 2026-02-04 | Turner William D. | +25,000 | - | - |
| 2026-02-04 | JOHNSON DAVID LEE | +40,000 | - | - |
| 2026-02-04 | JOHNSON DAVID LEE | +20,000 | - | - |
| 2025-12-15 | Turner William D. | -10,000 | - | - |
| 2025-12-15 | Turner William D. | -10,000 | $50.0767 | $500,767 |
| 2025-12-15 | Turner William D. | +10,000 | $15.53 | $155,300 |
| 2025-12-11 | ENRIGHT PATRICK G | +5,882 | $42.5 | $249,985 |
| 2025-12-08 | Turner William D. | -10,000 | - | - |
| 2025-12-08 | Turner William D. | -10,000 | $45.3053 | $453,053 |
| 2025-12-08 | Turner William D. | +10,000 | $15.53 | $155,300 |
| 2025-12-03 | Turner William D. | -10,000 | - | - |
| 2025-12-03 | Turner William D. | -10,000 | $40 | $400,000 |
| 2025-12-03 | Turner William D. | +10,000 | $15.53 | $155,300 |
| 2025-11-25 | Meyers James R | +25,000 | - | - |
| 2025-11-21 | Carter Jason S | -3,864 | $27.8204 | $107,498 |
| 2025-11-13 | Young Joseph R | -10,000 | - | - |
| 2025-11-13 | Young Joseph R | +10,000 | $3.9396 | $39,396 |
| 2025-11-11 | Young Joseph R | -15,000 | $29.0583 | $435,875 |